LeMaitre Vascular (NASDAQ:LMAT) Price Target Raised to $105.00

LeMaitre Vascular (NASDAQ:LMAT) had its price objective raised by equities research analysts at Barrington Research from $95.00 to $105.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s price target indicates a potential downside of 7.64% from the company’s current price.

A number of other equities analysts also recently commented on the company. Wells Fargo & Company increased their price objective on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a report on Thursday. Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Cantor Fitzgerald restated a “neutral” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research note on Monday, November 10th. Citizens Jmp lifted their price objective on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research note on Thursday. Finally, Roth Mkm reiterated a “buy” rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $106.50.

LeMaitre Vascular Trading Up 24.4%

LMAT stock traded up $22.31 during mid-day trading on Thursday, reaching $113.69. 1,266,629 shares of the stock traded hands, compared to its average volume of 174,535. LeMaitre Vascular has a 52-week low of $71.42 and a 52-week high of $115.33. The stock’s fifty day moving average is $85.98 and its 200-day moving average is $88.12. The company has a market cap of $2.58 billion, a P/E ratio of 49.00, a P/E/G ratio of 2.01 and a beta of 0.72. The company has a current ratio of 13.58, a quick ratio of 11.45 and a debt-to-equity ratio of 0.44.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.67 by $0.01. The business had revenue of $64.45 million during the quarter, compared to analysts’ expectations of $62.98 million. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.LeMaitre Vascular’s revenue was up 15.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, sell-side analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Parkside Financial Bank & Trust raised its holdings in LeMaitre Vascular by 1,913.3% in the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 287 shares during the period. Cornerstone Planning Group LLC grew its holdings in shares of LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 283 shares during the period. MAI Capital Management bought a new stake in shares of LeMaitre Vascular in the 3rd quarter valued at $38,000. First Horizon Corp acquired a new stake in LeMaitre Vascular during the 3rd quarter worth $39,000. Finally, Geneos Wealth Management Inc. raised its stake in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares during the period. Institutional investors own 84.64% of the company’s stock.

Key Stories Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat consensus: LeMaitre reported $0.68 EPS vs. $0.67 expected and revenue of $64.45M (up 15.7% YoY), showing strong margin and ROE metrics that underpin the rally. MarketBeat Earnings Report
• Positive Sentiment: Management raised guidance: Q1 FY2026 EPS guidance of $0.640–0.690 (above consensus) and FY2026 EPS guidance of $2.810–3.010 (well above consensus) — a material tailwind to near- and full-year expectations. Company Press Release (Guidance)
• Positive Sentiment: Dividend increase: Board raised the quarterly dividend 25% to $0.25 per share (annualized yield ~1.1%), signaling confidence in cash flow and supporting investor appetite for the stock.
• Positive Sentiment: Analyst support — Roth MKM reaffirmed a Buy and lifted its price target to $117 (from $108), and Citizens JMP bumped its target to $118 with a Market Outperform/Outperform view — additional validation for the beat/guidance. Benzinga (Roth MKM) TickerReport (Citizens JMP)
• Neutral Sentiment: Earnings call transcript available for detail: the transcript provides color on demand trends, product mix and margin drivers for investors doing deeper due diligence. Seeking Alpha Transcript
• Neutral Sentiment: Analyst commentary pieces (coverage/insights) are circulating that explain expectations and valuation vs. peers; useful for refining models but not immediate catalysts. Benzinga Insights
• Negative Sentiment: Offsetting note from Wells Fargo: they raised their price target to $94 but hold an Equal Weight rating — the $94 target is materially below the current market level, representing downside risk if sentiment reverses or guidance is discounted. Benzinga (Wells Fargo)

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.